Skip to content

Released Nov 4, 2025, after the close

10-Q filed Nov 4, 2025, 35 days after period end · 0001193125-25-264695

Q3 2025 · 10-Q
Revenue$19.55M−11.5% vs Q3 2024−10.2% vs Q2 2025
Net Income-$34.69MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.09N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$9,484,000−21.8%
Operating Income-$32,938,000N/M
Operating Cash Flowderived-$22,202,000N/M
Free Cash Flowderived-$23,088,000N/M
Margins · derived
Gross margin48.5%−6.4 pt vs Q3 2024
Operating margin-168.5%−47.6 pt vs Q3 2024
Net margin-177.4%−55.4 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$19.55M$22.09M$25.37M$25.65M
Net Income-$34.69M-$26.94M-$21.00M-$29.43M
EPS Diluted-$0.09-$0.07-$0.27-$0.37

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR